SYDNEY, Nov. 25, 2025 /PRNewswire/ — One of Australia’s largest medical supply companies is celebrating its unique warehousing and supply chain strategy that has seen it grow into a leading manufacturer, importer, and supplier to more than 20 key industries.

Livingstone International supplies more than 65,000 essential health, hygiene, education, beauty, and hospitality products to industries including aged care, schools and universities, hair and skin clinics, pharmacy, dental, mining, and government.

Livingstone International Managing Director, Daniel Linn, said the company has now been in operation for more than 40 years and its success rests on its unique No Backorder Policy.

“Livingstone International has invested in millions of cubic metres of warehousing here in Australia, where we can hold up to a year’s worth of supplies for each of our key clients.”

“Livingstone stocks more than $48 million dollars’ worth of inventory. Our depth of inventory and domestic warehousing means there’s no disruption to the supply chain, which is critical for the industries we work with,” Mr Linn said.

It’s a lesson that was learned during COVID, when many organisations and government turned to Livingstone for key supplies.

“The reality is much of what we rely on in Australia is manufactured overseas and imported. That process often requires a two to three month waiting period before products arrive.”

“At Livingstone, we have the stock here in Australia ready to distribute, while also locally manufacturing 120 products, to ensure they’re there for when our clients need them,” he said.

Livingstone remains proudly Australian owned, with an international footprint across 120 countries.

“When Livingstone was founded in 1984, we focused on medical and healthcare supplies, but we’ve now undergone major diversification,” Mr Linn said.

“The rationale for expansion was: if we can supply products to people when they are unwell, why not also offer items for when they are well? The goal was to meet needs 365 days a year and this approach became a guiding principle for determining which industries to branch into.

“Among our 25,000 customers are 149 major public hospitals which depend on Livingstone for kitchen supplies, 22 airlines in which we’re involved with food prep, a pathology market leader with more than 500 delivery points, and we supply lab equipment and coats to the biggest mining company in the country.”  

Mr Linn said while this year marks a major milestone, the future is full of opportunity.

“We’re already adopting some of the latest technology in automation and AI, we are diversifying our supply chain across multiple countries, and our IT infrastructure is already driving greater growth across our B2C market,” he said.

“We look forward to continuing to help secure Australia’s supply chain and provide essential services and key industries with the products they need to serve Australians every day.”

SYDNEY, Nov. 25, 2025 /PRNewswire/ — EcoFlow, a global innovator in residential energy storage and smart home energy ecosystems, has formally partnered with Go Solar Australia to expand the availability of EcoFlow’s advanced home battery systems to solar retailers, installers and engineering partners nationwide.

With demand surging for reliable residential storage solutions that address rising energy costs, grid instability and the need for flexible solar-integration options, the partnership delivers significant commercial benefits to the Australian solar and storage sector.

The collaboration leverages Go Solar Australia’s extensive distribution, warehouse and installation network – providing trade professionals with streamlined access to EcoFlow’s high-efficiency LFP PowerOcean battery systems, scalable storage modules, and intelligent home energy-management technology.

Key Advantages for Installers & Industry Partners

• Superior engineering & safety 
  EcoFlow’s PowerOcean is built around durable LFP chemistry, recognised for its thermal stability and low risk of thermal runaway. Each battery module includes a dedicated fire-prevention system with multi-layer thermal insulation, temperature monitoring and automatic shut-off mechanisms designed to isolate abnormal conditions before escalation. The system is housed in an IP65-rated enclosure, protecting components from dust, rain and harsh outdoor environments commonly encountered in Australian installations. Together, these measures support safe installation, long-term reliability and user confidence.
• Expanded product portfolio
  Installers gain access to EcoFlow’s growing residential storage ecosystem – engineered for fast installation, modular expansion up to 180kWh and system-wide safety.
• Flexible system design
  Scalable capacity allows installers to serve diverse residential use cases – from small urban homes to high-demand family properties.
• Local supply chain support
  Backed by Go Solar Australia’s multi-state warehouses, technical support and national installer base.
• Third-party compatibility 
  PowerOcean integrates smoothly with a wide range of third-party inverters, rooftop solar systems, smart thermometers and home-energy devices. This gives installers the flexibility to pair EcoFlow storage with both new builds and existing residential setups without limiting system design options.
• Smart energy optimisation 
  PowerOcean’s onboard energy-management capabilities continually analyse household consumption, solar production and tariff patterns to optimise charging and discharging automatically. This ensures installers can deliver systems that maximise self-consumption, improve overall efficiency and reduce long-term energy costs for homeowners.

“Our partnership with Go Solar Australia unlocks new opportunities for solar retailers and installers seeking high-quality, fast-to-deploy and future-proof residential energy systems,” said, EcoFlow Craig Bilboe, Country Manager, Australia & New Zealand. “EcoFlow is committed to supporting the Australian solar industry with premium technology, strong warranties and excellent local support.”

“EcoFlow’s offerings are a natural fit for our installer network,” said Lewis Sheppard, National Sales Director of Go Solar Australia. “The systems are reliable, scalable and engineered for professional installation – exactly what our trade partners look for. We’re proud to help accelerate EcoFlow’s growth in the Australian market.”

About EcoFlow

EcoFlow is a global leader in eco-friendly energy solutions, committed to powering a sustainable future. Since its founding in 2017, EcoFlow has focused on creating flexible, innovative, and reliable power solutions for homes, outdoor adventures, and on-the-go lifestyles. With headquarters in the USA, Germany, and Japan, EcoFlow has empowered over 5 million users across 140 markets worldwide.

About Go Solar Australia

Go Solar Australia is a leading national provider of solar and battery engineering, installation and wholesale services, supporting trade partners in delivering reliable and efficient renewable energy systems across the country.

Fisher Investments was certified by global authority on workplace culture

SYDNEY, Nov. 25, 2025 /PRNewswire/ — Fisher Investments Australia and its US-based parent company, Fisher Investments, were certified by Great Place to Work^®, an independent, global authority on workplace culture and employee experience.

Great Place to Work^® certifies companies based on anonymous employee survey results across key factors including compensation, benefits, career advancement opportunities, competence of management and overall workplace atmosphere. Survey feedback revealed Fisher Investments Australia employees believe the company provides a fair, welcoming and service-focused work environment.

“We are incredibly proud of this recognition from Great Place to Work^®,” said Fisher Investments’ CEO Damian Ornani, adding, “This honour highlights our dedication to fostering a culture where employees feel valued, motivated and empowered to thrive. We know that by investing in our people and their growth, we create a stronger foundation to deliver exceptional service and help more clients reach their financial goals.”

Fisher Investments and its affiliates are hiring for a variety of roles globally. Visit FisherCareers.com to learn more about career opportunities. For more details on the Great Place to Work^® certification process, please visit www.greatplacetowork.com.au/our-methodology.

About Fisher Investments Australia^®
Fisher Investments Australia^® is a trademark of Fisher Investments Australasia Pty Ltd (ABN 86 159 670 667, AFSL 433312), which provides services to wholesale clients only and outsources portfolio management to its parent company, Fisher Asset Management, LLC (AR 001292046), which does business in the United States as Fisher Investments. Fisher Investments Australasia Pty Ltd was established in 2013 and is based in Sydney. For more information on Fisher Investments Australia, please visit https://www.fisherinvestments.com/en-au.

About Fisher Investments
Fisher Investments is an independent, fee-only investment adviser. As of 30/09/2025, Fisher Investments and its subsidiaries manage over A$547 billion across three principal businesses—Institutional, US Private Client and Private Client International. Founder and Executive Chairman Ken Fisher wrote the Forbes “Portfolio Strategy” column for over 32 years until 31/12/2016, making him the longest continuously running columnist in the magazine’s history. He now writes monthly, native language columns in 27 major media organs around the world—including the Australian Financial Review—spanning more countries and more languages in more total reach than any other, non-syndicated columnist of any type ever. Ken appears regularly on major TV news like Fox Business and News, BBC, Sky News, BNN Bloomberg and CNN International. Ken has written 11 investing and finance books, including four New York Times bestsellers. For more information about Fisher Investments, visit www.fisherinvestments.com.

Media Contacts

Great Place to Work Certified Sep. 2025 – Sep. 2026

Logo – https://laotiantimes.com/wp-content/uploads/2025/11/fisher_investments_australia_logo.jpg

Photo – https://laotiantimes.com/wp-content/uploads/2025/11/fisher_investments_australia_australia_certification_badge.jpg

Launch Trailer Drops, Featuring Sung Jinwoo’s Ascension to Become the Ultimate Monarch of Shadows

SEOUL, South Korea, Nov. 25, 2025 /PRNewswire/ — Solo Leveling: ARISE OVERDRIVE, developed by Netmarble Neo and published by Netmarble, is available now on Steam and Xbox PC, with a new trailer to celebrate its official release.

Based on the worldwide megahit webtoon Solo Leveling, this action RPG delivers an original take on a beloved adventure that fans have been waiting for. Complete with gorgeously animated combat, deep progression systems, and dynamic battles, the game brings to life the story of Hunter Sung Jinwoo, who rises from humble beginnings to become the world’s strongest hunter – the Ultimate Shadow Monarch.

First showcased to fans at TwitchCon San Diego last month to an enthusiastic reception, Solo Leveling: ARISE OVERDRIVE has built momentum through the demo release on November 17 and Advanced Access that began on November 21. Now, the game is officially available worldwide, inviting all players to become Sung Jinwoo themselves. 

Through Story Mode, players will be able to create their own perfect version of Sung Jinwoo, customizing his appearance, skills, and playstyle as they unleash their ultimate power. By recruiting Hunters to fill out their ranks and battling bosses in 4-player co-op raids, players will be able to strengthen their teams and showcase their skills across the game’s many challenges.

Solo Leveling: ARISE OVERDRIVE is available now on Steam and Xbox PC for $39.99. 

Visit the official website and Steam page, and follow the game’s channels on Twitch, YouTube and Discord, for more information, or wishlist the game on Xbox.

About Netmarble Corporation

Founded in Korea in 2000, Netmarble Corporation is a leading global game developer and publisher. Through acclaimed franchises and strategic partnerships with top-tier IP holders, the company delivers innovative and engaging gaming experiences to audiences worldwide. As a parent company of Kabam, SpinX Games, Jam City, and a major shareholder of HYBE and NCSOFT, Netmarble’s diverse portfolio includes Solo Leveling: ARISE, Seven Knights Re: BIRTH, Raven2, MARVEL Future Fight, and The Seven Deadly Sins: Grand Cross. More information can be found at http://company.netmarble.com.

• The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies.
• The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues and immune systems from the model library. This significantly improves resolution in identifying the differentiating advantages of multi-target combinations—uncovering subtle distinctions across genes, molecules, cells, tissues, and clinical phenotypes.

BOSTON and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ — HKeyBio, a global leading CRO specializing in preclinical and translational research for autoimmune and allergic disease drug development, has officially launched the upgraded HKEY-AIDMD 3.0 platform. This platform includes: (1) a four-dimensional model library of nearly 300 autoimmune and allergic disease models, and (2) a comprehensive spatiotemporal single-cell and spatial omics database derived from these models. The platform is designed to significantly enhance prediction accuracy for clinical translation of multi-target combination therapies.

Autoimmune and allergic diseases stem from dysregulated immune networks across three major immunological domains: multiple cellular components, diverse cytokine networks, and interconnected signaling pathways. These conditions involve aberrant activity of immune cell populations such as T cells, B cells, dendritic cells, and granulocytes; dysregulated cytokines including IL-6, IL-4, TNF; and perturbed signaling pathways such as JAK/STAT, NF-κB, BTK, along with mechanisms of immune tolerance. Since single-target drugs may demonstrate limited efficacy in certain patient populations, multi-target combinations can more comprehensively modulate pathological networks and improve therapeutic outcomes. Moreover, due to disease heterogeneity, multi-target therapies can more precisely match patient-specific pathogenic profiles, supporting personalized treatment strategies.

However, multi-target drug development faces major technical and clinical challenges. The number of possible combinations increases exponentially due to the diversity of targets, dosing regimens, and mechanisms of action. With limited resources, prioritizing the most effective and safest combinations is an urgent unmet need. Achieving optimal combinations requires accurate mapping of key pathogenic nodes within disease networks and identifying predictive biomarkers for treatment response.

HKeyBio’s newly upgraded HKEY-AIDMD 3.0 provides a practical solution to the “optimal multi-target combination” challenge. Built upon deep mechanistic insights into autoimmune and allergic diseases, HKeyBio has developed four-dimensional model pools across multiple species, strains, and induction strategies to simulate various disease subtypes and endotypes. These model pools enable evaluation of in vivo interactions, feedback mechanisms, and synergy of multi-target combinations. Using systems biology approaches, including gene regulatory networks, protein-protein interaction networks, and pathway topology analysis, HKeyBio identifies key nodal and bottleneck targets in disease networks. Machine learning methods further support predictive modeling of combination outcomes and discovery/validation of biomarkers such as gene signatures, single-cell immune profiles, and cytokine panels.

The HKEY-AIDMD 3.0 platform not only enhances predictive value for multi-target efficacy but also significantly boosts developability and commercial partnering value. By integrating multi-indication 4D model pools with spatiotemporal omics, the platform offers critical support for new drug development in rheumatology, immunology, and allergy. It improves mechanistic accuracy, provides high-resolution multi-dimensional biomarker discovery, and increases reliability in predicting therapeutic responses across multiple pathways.

About the HKeyBio HKEY-AIDMD 3.0 Platform

The HKEY-AIDMD 3.0 model library covers nearly 300 autoimmune and allergy-related disease models. For major indications, HKeyBio has built 4D model pools that simulate clinical heterogeneity to support mechanism-based model selection for multi-target combination evaluation. These include dermatologic models (atopic dermatitis, urticaria, pruritus, hidradenitis suppurativa, psoriasis), respiratory models (asthma, COPD, pulmonary fibrosis), gastrointestinal models (IBD, Crohn’s disease), and rheumatologic models (SLE, cutaneous lupus, Sjögren’s syndrome, rheumatoid arthritis, systemic sclerosis, multiple sclerosis), among many others.

The HKEY-AIDMD 3.0 omics database encompasses spatiotemporal single-cell and spatial omics across tissues and immune compartments from all models. Using systems biology methods—including gene expression networks, protein–protein interaction networks, and signaling topology analysis—combined with machine learning, the platform predicts multi-target drug combination effects and validates biomarkers for efficacy and safety, dramatically improving the resolution in differentiating target-combination strategies.

HKeyBio is an industry-leading CRO specializing in pharmacology and translational research for autoimmune diseases—focused, dedicated, and deeply experienced in autoimmune innovation.
For more information, please visit www.hkeybio.com

For inquiries, please contact: us.bd@hkeybio.com

• Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

• BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood

FLORENCE, Italy and NEW YORK, Nov. 24, 2025 /PRNewswire/ — The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, today announced that the company will present new data related to ELZONRIS® (tagraxofusp-erzs) at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, December 6-9^th.

The presentations include an oral session highlighting results from a triplet therapy combining tagraxofusp, azacitidine, and venetoclax, which demonstrated both efficacy (high response and bridge to transplant rates) and tolerability in individuals with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

“At Menarini Stemline, our commitment to transforming the lives of people living with difficult-to-treat cancers is unwavering,” said Elcin Barker Ergun, CEO of the Menarini Group. “These data demonstrate that tagraxofusp plays an important role in both monotherapy and combination settings for the treatment of BPDCN, and that it also has potential to help patients living with other aggressive hematologic malignancies, where more effective treatment options are desperately needed.”

See below for full details of the Menarini Group/Stemline Therapeutics’ upcoming presentations and publication:

American Society of Hematology (ASH) Annual Meeting 2025

*Denotes investigator sponsored research or collaborative research.

ELZONRIS was approved by the FDA in December 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve and previously-treated populations. In January 2021, ELZONRIS was approved by the European Commission. 

About BPDCN

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow and blood. It can also affect other parts of the body, such as the lymph nodes, spleen, liver and central nervous system. Approximately 85% to 90% of patients develop skin lesions as a first sign of BPDCN. BPDCN affects all people of all races and geographic locations, with the global prevalence likely in the range of 0.4 – 0.5 per 100,000 people annually. While BPDCN affects both men and women of all ages, 75% of cases occur in men, with a median age at onset of 60-70 years. A key characteristic of BPDCN cancer cells is their high expression of a protein called CD123, which can be observed on the surface of the cells. This makes CD123 a crucial diagnostic marker as well as a prime target for precision therapies to strike the cancer directly.

About ELZONRIS^® (tagraxofusp-erzs)

U.S. Indication: ELZONRIS (tagraxofusp-erzs) is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

Full prescribing information for the U.S. can be found at www.elzonris.com.

IMPORTANT SAFETY INFORMATION, ELZONRIS®

Boxed WARNING: CAPILLARY LEAK SYNDROME

• Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended.

Warnings and Precautions

Capillary Leak Syndrome

Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with ELZONRIS. In patients receiving ELZONRIS in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range – 1 to 46 days), and all but 5 patients experienced an event in Cycle 1.

Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability.

Hypersensitivity Reactions

ELZONRIS can cause severe hypersensitivity reactions. In patients receiving ELZONRIS in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with ELZONRIS and were Grade ≥ 3 in 7% (9/122). Manifestations of hypersensitivity reported in ≥ 5% of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur.

Hepatotoxicity

Treatment with ELZONRIS was associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4 AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption.

Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Withhold ELZONRIS temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved.

Adverse Reactions

Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.

 Please see full Prescribing Information, including Boxed WARNING.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About The Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com. 

About Stemline Therapeutics Inc.

Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.